Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Connective Tissue Disease: later-stage trial registry
1 of 3 indexed Connective Tissue Disease trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Connective Tissue Disease: 3 US clinical trials tracked, 1 recruiting.
Connective Tissue Disease is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is National Human Genome Research Institute (NHGRI), running 1 of these trials.
Enrollment posture brief
Registry condition connective-tissue-disease
OPEN 1 | RECR 33% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Connective Tissue Disease lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Connective Tissue Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Connective Tissue Disease is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
Children's Hospital Medical Center, Cincinnati
NCT07477197
Study of Heritable Connective Tissue Disorders
National Human Genome Research Institute (NHGRI)
NCT00001641
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Johns Hopkins University
NCT01042158
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Connective Tissue Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Connective Tissue Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Connective Tissue Disease page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Connective Tissue Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Human Genome Research Institute (NHGRI) sponsors the most Connective Tissue Disease trials on record, review their full trial history before evaluating a specific study. See National Human Genome Research Institute (NHGRI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Connective Tissue Disease condition card totals 3 registered trials; most-linked intervention tadalafil and ambrisentan upfront combination therapy; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.